Meeting
2018 Genitourinary Cancers Symposium
Patterns of response to androgen deprivation therapy in younger patients with locally advanced or metastatic prostate cancer.
Authors
Matthew Keating
Roger Williams Medical Center, Providence, RI
Matthew Keating , Lisa Giscombe , Andre Desouza , Shiva Kumar Reddy Mukkamalla , Ritesh Rathore
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer, Urothelial Carcinoma, and Penile, Urethral, and Testicular Cancers
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 36, 2018 (suppl 6S; abstr 324)
DOI
10.1200/JCO.2018.36.6_suppl.324
Abstract #
324
Poster Bd #
C15
Abstract Disclosures
Similar Posters
Poster
2018 Genitourinary Cancers Symposium
Phase II randomized study of abiraterone acetate plus ADT versus apalutamide versus abiraterone and apalutamide in patients with advanced prostate cancer with non-castrate testosterone levels. (LACOG 0415).
First Author: Fernando C. Maluf
Poster
2019 Genitourinary Cancers Symposium
Toxicity results from a novel phase I/II trial of VMAT radiotherapy to prostate and pelvic nodes plus six cycles of radium-223 in mCSPC metastatic to bone post ADT and docetaxel.
First Author: Joe O'Sullivan
Poster
2018 Genitourinary Cancers Symposium
Real world outcomes of upfront docetaxel for hormone naïve metastatic prostate cancer in an ethnically diverse inner-city population.
First Author: Surabhi Pathak
Poster
2023 ASCO Annual Meeting
The relationship between a priori defined prognostic risk groups and and overall survival (OS) in men with metastatic hormone sensitive prostate cancer (mHSPC).
First Author: Susan Halabi